ENCORE - A Randomized Double-Blind Placebo-Controlled Active Comparator Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)

Brief description of study

The purpose of this study is to evaluate the effect and safety of amikacin liposome inhalation suspension (ALIS) treatment on patient-reported symptoms in patients newly diagnosed with NTM lung infection caused by MAC who have not started treatment.

Clinical Study Identifier: s20-01186
ClinicalTrials.gov Identifier: NCT04677569
Principal Investigator: Doreen J Addrizzo-Harris.
Other Investigator: Rany Condos.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.